UA41290C2 - Гетероариламіни, фармацевтична композиція, спосіб інгібування холінестерази у ссавців, спосіб покращення пам'яті - Google Patents
Гетероариламіни, фармацевтична композиція, спосіб інгібування холінестерази у ссавців, спосіб покращення пам'ятіInfo
- Publication number
- UA41290C2 UA41290C2 UA94005424A UA94005424A UA41290C2 UA 41290 C2 UA41290 C2 UA 41290C2 UA 94005424 A UA94005424 A UA 94005424A UA 94005424 A UA94005424 A UA 94005424A UA 41290 C2 UA41290 C2 UA 41290C2
- Authority
- UA
- Ukraine
- Prior art keywords
- phenyl
- heteroarylamines
- alkyl
- ring
- mentioned
- Prior art date
Links
- 206010048650 Cholinesterase inhibition Diseases 0.000 title 1
- 241000124008 Mammalia Species 0.000 title 1
- 230000006993 memory improvement Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000005605 benzo group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- -1 benzyloxy, hydroxy, phenyl Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000005241 heteroarylamino group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Control Of El Displays (AREA)
- Control Of Indicators Other Than Cathode Ray Tubes (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Гетероаріламіни загальної формули (I): де один з R2, R3 і бічний ланцюг, що містить >C=Z , можуть бути, необов'язково, приєднані переважно до атому вуглецю, відміченому зірочкою, в кільці В, ніж до атому кільця А кільце А представляє бензо R1 представляє фенил, фенил(С1-С6) алкіл, циннаміл або гетероарилметил, де гетероарильний залишок зазначеного гетероарилметилу, вибраний з імідазоло, тіазоло, тієно, піридо і ізоксазоло, і де зазначені фенил і зазначений гетероарильний залишок можуть бути, необов'язково, заміщені одним або двома замісниками, незалежно вибраними з (С1-С6) алкілу, (С1-С4) алкокси і галоїду, R2 і R3 незалежно вибрані з водню, (С1-С6) алкокси, (С1-С6) алкілу, необов'язково заміщеного від одного до трьох атомів фтору, бензилокси, гідрокси, фенилом, бензилом, галоїдом, нітро, ціано, COOR4, CONHR4, NR4R5, NR4 СOR5, SОрСН2фенилом, де р дорівнює 0,1 або 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77128391A | 1991-10-03 | 1991-10-03 | |
| PCT/US1992/007230 WO1993007140A1 (en) | 1991-10-03 | 1992-08-31 | Heteroaryl amines as novel acetyl cholinesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA41290C2 true UA41290C2 (uk) | 2001-09-17 |
Family
ID=25091318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA94005424A UA41290C2 (uk) | 1991-10-03 | 1992-08-31 | Гетероариламіни, фармацевтична композиція, спосіб інгібування холінестерази у ссавців, спосіб покращення пам'яті |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US5574046A (uk) |
| EP (1) | EP0606248B1 (uk) |
| JP (1) | JP2546785B2 (uk) |
| KR (1) | KR0170458B1 (uk) |
| CN (1) | CN1035615C (uk) |
| AP (1) | AP314A (uk) |
| AT (1) | ATE235490T1 (uk) |
| AU (1) | AU667053B2 (uk) |
| BG (1) | BG61727B1 (uk) |
| BR (1) | BR9206577A (uk) |
| CA (1) | CA2119647C (uk) |
| CZ (1) | CZ290807B6 (uk) |
| DE (2) | DE9290112U1 (uk) |
| DK (1) | DK0606248T3 (uk) |
| EG (1) | EG21481A (uk) |
| ES (1) | ES2193137T3 (uk) |
| FI (1) | FI116939B (uk) |
| HU (1) | HU225049B1 (uk) |
| IL (1) | IL103274A (uk) |
| IS (1) | IS1745B (uk) |
| MA (1) | MA22672A1 (uk) |
| MX (1) | MX9205678A (uk) |
| NO (1) | NO308533B1 (uk) |
| NZ (1) | NZ244601A (uk) |
| OA (1) | OA09895A (uk) |
| PH (1) | PH31290A (uk) |
| PL (3) | PL171693B1 (uk) |
| PT (1) | PT100917B (uk) |
| RO (1) | RO112868B1 (uk) |
| RU (1) | RU2100357C1 (uk) |
| SG (1) | SG52618A1 (uk) |
| TW (1) | TW263504B (uk) |
| UA (1) | UA41290C2 (uk) |
| UY (1) | UY23484A1 (uk) |
| WO (1) | WO1993007140A1 (uk) |
| ZA (1) | ZA927589B (uk) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5620973A (en) * | 1993-11-30 | 1997-04-15 | Takeda Chemical Industries, Ltd. | Tetracyclic condensed heterocyclic compounds and their use |
| EP0976404A3 (en) * | 1998-07-30 | 2001-06-27 | Pfizer Products Inc. | A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal |
| US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| EP1118322A4 (en) | 1998-09-30 | 2004-10-20 | Takeda Chemical Industries Ltd | MEDICINES THAT IMPROVE BLADDER DRAINING POWER |
| SE9902268D0 (sv) * | 1999-06-16 | 1999-06-16 | Astra Ab | Pharmaceutically active compounds |
| CN1317276C (zh) * | 2000-09-29 | 2007-05-23 | 中国科学院上海药物研究所 | 一类吲哚基哌啶类化合物及其制备方法和用途 |
| IL154685A0 (en) * | 2000-10-20 | 2003-09-17 | Biovitrum Ab | 2-,3-,4-, or 5-substituted-n1-(benzensulfonyl) indoles and their use in therapy |
| JP2006505571A (ja) * | 2002-10-15 | 2006-02-16 | リゲル ファーマシューテイカルズ、インコーポレイテッド | 置換されたインドール及びｈｃｖ阻害剤としてのその使用 |
| US20060014801A1 (en) * | 2002-11-22 | 2006-01-19 | The Johns Hopkins University | Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs |
| WO2005112908A1 (en) * | 2004-05-14 | 2005-12-01 | The Johns Hopkins University | Method for improving cognitive function |
| EP1600447A1 (en) * | 2004-05-28 | 2005-11-30 | Neuropharma S.A.U. | Butyrylcholinesterase selective inhibitors |
| EP1753764B1 (en) | 2004-06-09 | 2008-10-29 | Glaxo Group Limited | Pyrrolopyridine derivatives |
| EP2425846A1 (en) * | 2004-12-23 | 2012-03-07 | Voyager Pharmaceutical Corporation | Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease |
| CN1808106B (zh) * | 2005-01-21 | 2010-11-24 | 中国科学院上海药物研究所 | 一种用核磁共振筛选乙酰胆碱酯酶抑制剂的方法 |
| ES2463766T3 (es) * | 2008-08-12 | 2014-05-29 | Zinfandel Pharmaceuticals, Inc. | Método de identificación de factores de riesgo de la enfermedad de Alzheimer |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| CN101503414B (zh) * | 2009-03-04 | 2013-10-30 | 沈阳药科大学 | 噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用 |
| KR20190082985A (ko) | 2009-10-02 | 2019-07-10 | 아벡신 에이에스 | 소염제 2-옥소티아졸 및 2-옥소옥사졸 |
| EP2533645B1 (en) | 2010-02-09 | 2016-07-27 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| WO2012096873A1 (en) | 2011-01-10 | 2012-07-19 | Zinfandel Pharmaceuticals, Inc. | Methods and drug products for treating alzheimer's disease |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| AU2014211489A1 (en) | 2013-01-29 | 2015-08-13 | Avexxin As | Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds |
| CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
| EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| CN103333163A (zh) * | 2013-07-09 | 2013-10-02 | 广州中医药大学 | 一种苯并呋喃类衍生物及其制备方法和应用 |
| GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
| CN107810002B (zh) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
| GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| CN107141266B (zh) * | 2017-06-28 | 2019-04-09 | 佳木斯大学附属第一医院 | 一种用于治疗阿尔茨海默病的杂环化合物及其制备方法 |
| CN115466211B (zh) * | 2022-06-09 | 2024-02-23 | 中国人民解放军空军军医大学 | 一种n-苯基喹啉-4-胺类化合物及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL100127C (uk) * | 1954-04-28 | |||
| FR2334358A1 (fr) * | 1975-12-12 | 1977-07-08 | Sogeras | Nouveaux medicaments derives de l'indole |
| US4122265A (en) * | 1976-05-21 | 1978-10-24 | Hoffmann-La Roche Inc. | Derivatives of 3-phenylisoindole-1-carboxylic acid |
| ZA815541B (en) * | 1980-08-12 | 1983-03-30 | Glaxo Group Ltd | Heterocyclic compounds |
| GB8615562D0 (en) * | 1986-06-25 | 1986-07-30 | Maggioni Farma | Aminoalcohols |
| KR910006138B1 (ko) * | 1986-09-30 | 1991-08-16 | 에자이 가부시끼가이샤 | 환상아민 유도체 |
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| IT1226100B (it) * | 1988-07-07 | 1990-12-10 | Dompe Farmaceutici Spa | Derivati benzimidazolici farmacologicamente attivi. |
| FR2640266B2 (fr) * | 1988-07-12 | 1992-07-10 | Synthelabo | Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique |
| US4908372A (en) * | 1988-10-13 | 1990-03-13 | Merrell Dow Pharmaceuticals Inc. | Antihistaminic piperidinyl benzimidazoles |
| JP2969359B2 (ja) * | 1989-01-13 | 1999-11-02 | 武田薬品工業株式会社 | 環状アミン化合物 |
| US5064840A (en) * | 1989-08-03 | 1991-11-12 | Merrell Dow Pharmaceuticals | Anti-psychotic piperidylbenzimidazole compounds |
| TW197442B (uk) * | 1990-02-08 | 1993-01-01 | Pfizer | |
| US5116846A (en) * | 1990-03-28 | 1992-05-26 | Du Pont Merck Pharmaceutical Company | N-aralkyl piperidine derivatives as psychotropic drugs |
| TW197435B (uk) * | 1990-11-22 | 1993-01-01 | Takeda Pharm Industry Co Ltd | |
| NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| FI943727A0 (fi) * | 1992-02-13 | 1994-08-12 | Merrell Dow Pharma | Piperidinyylitiasyklisiä johdannaisia |
| TW226019B (uk) * | 1992-03-23 | 1994-07-01 | Sankyo Co |
-
1992
- 1992-08-29 TW TW081106843A patent/TW263504B/zh active
- 1992-08-31 RO RO94-00533A patent/RO112868B1/ro unknown
- 1992-08-31 ES ES92918761T patent/ES2193137T3/es not_active Expired - Lifetime
- 1992-08-31 BR BR9206577A patent/BR9206577A/pt not_active Application Discontinuation
- 1992-08-31 WO PCT/US1992/007230 patent/WO1993007140A1/en not_active Ceased
- 1992-08-31 CZ CZ1994785A patent/CZ290807B6/cs not_active IP Right Cessation
- 1992-08-31 PL PL92312752A patent/PL171693B1/pl not_active IP Right Cessation
- 1992-08-31 CA CA002119647A patent/CA2119647C/en not_active Expired - Fee Related
- 1992-08-31 JP JP5506442A patent/JP2546785B2/ja not_active Expired - Fee Related
- 1992-08-31 DE DE9290112U patent/DE9290112U1/de not_active Expired - Lifetime
- 1992-08-31 PL PL92312751A patent/PL171984B1/pl not_active IP Right Cessation
- 1992-08-31 DK DK92918761T patent/DK0606248T3/da active
- 1992-08-31 AU AU25196/92A patent/AU667053B2/en not_active Ceased
- 1992-08-31 US US08/211,044 patent/US5574046A/en not_active Expired - Lifetime
- 1992-08-31 PL PL92303096A patent/PL171669B1/pl not_active IP Right Cessation
- 1992-08-31 UA UA94005424A patent/UA41290C2/uk unknown
- 1992-08-31 DE DE69232976T patent/DE69232976T2/de not_active Expired - Fee Related
- 1992-08-31 SG SG1996006904A patent/SG52618A1/en unknown
- 1992-08-31 KR KR1019940701066A patent/KR0170458B1/ko not_active Expired - Fee Related
- 1992-08-31 RU RU9494019972A patent/RU2100357C1/ru not_active IP Right Cessation
- 1992-08-31 AT AT92918761T patent/ATE235490T1/de not_active IP Right Cessation
- 1992-08-31 EP EP92918761A patent/EP0606248B1/en not_active Expired - Lifetime
- 1992-08-31 HU HU9400952A patent/HU225049B1/hu unknown
- 1992-09-07 AP APAP/P/1992/000421A patent/AP314A/en active
- 1992-09-15 PH PH44935A patent/PH31290A/en unknown
- 1992-09-24 IL IL10327492A patent/IL103274A/en not_active IP Right Cessation
- 1992-09-25 IS IS3919A patent/IS1745B/is unknown
- 1992-09-30 CN CN92112079A patent/CN1035615C/zh not_active Expired - Fee Related
- 1992-09-30 EG EG58192A patent/EG21481A/xx active
- 1992-10-01 PT PT100917A patent/PT100917B/pt not_active IP Right Cessation
- 1992-10-02 UY UY23484A patent/UY23484A1/es not_active IP Right Cessation
- 1992-10-02 NZ NZ244601A patent/NZ244601A/en not_active IP Right Cessation
- 1992-10-02 ZA ZA927589A patent/ZA927589B/xx unknown
- 1992-10-02 MX MX9205678A patent/MX9205678A/es unknown
- 1992-10-02 MA MA22956A patent/MA22672A1/fr unknown
-
1994
- 1994-03-18 OA OA60484A patent/OA09895A/en unknown
- 1994-03-30 NO NO941179A patent/NO308533B1/no unknown
- 1994-03-31 BG BG98689A patent/BG61727B1/bg unknown
- 1994-03-31 FI FI941518A patent/FI116939B/fi active IP Right Grant
-
1997
- 1997-10-24 US US08/957,639 patent/US6124321A/en not_active Expired - Fee Related
-
1999
- 1999-11-11 US US09/438,712 patent/US6303633B1/en not_active Expired - Fee Related
-
2001
- 2001-08-23 US US09/935,903 patent/US20020049210A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA41290C2 (uk) | Гетероариламіни, фармацевтична композиція, спосіб інгібування холінестерази у ссавців, спосіб покращення пам'яті | |
| PL348769A1 (en) | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents | |
| PH17114A (en) | Novel(piperidinylalkyl)quinazoline derivatives | |
| CS89587A2 (en) | Zpusob vyroby arylcyklobutylalkylaminu | |
| MY104850A (en) | N-phenyloyrazole derivatives | |
| EP0173520A3 (en) | Tricyclic oxindole antiinflammatory agents | |
| TW283147B (uk) | ||
| ES8707525A1 (es) | Un procedimiento para la preparacion de nuevas isoindolinil-alquilpiperazinas | |
| EP0259835A3 (en) | Pyridazinone derivatives | |
| TW324009B (en) | Pyrazole condensation ring derivative, its production process and its use as androgen inhibitor | |
| EP0335979A4 (en) | Thienopyrimidine derivatives | |
| EP0315434A3 (en) | Pyridoxal hydrazone derivatives their production and use and pharmaceutical compositions containing the same | |
| ES8101071A1 (es) | Procedimiento para preparar nuevos derivados de (piridil-2)-2-tetrahidrotiofeno | |
| ES2010089A6 (es) | Procedimiento para la obtencion de n-oxidos de gamma-carbolina antipsicoticos. | |
| IE44449L (en) | Morphanthridines | |
| DE69301639D1 (de) | Tetrahydronaphtalenderivate, ihre Herstellung und ihre therapeutische Verwendung | |
| GR3026075T3 (en) | 5-(1-fluoro-vinyl)-1h-pyrimidine-2,4-dione derivatives useful as antineoplastic agents | |
| ES485990A1 (es) | Procedimiento de preparacion de un nuevo derivado de la per-hidrotiazina-1,3 | |
| DK434185A (da) | Quinolizinonforbindelser | |
| ES483236A1 (es) | Procedimiento de preparacion de derivados de pirazolidin- diona | |
| YU49158B (sh) | Heteroaril amini kao novi inhibitori acetilholinesteraze | |
| JPS5384991A (en) | Novel nitrogen-containing heterocyclic compound and its preparation |